Related Experiment Videos
Glucose-modified low density lipoprotein enhances human monocyte chemotaxis
S A Millican1, D Schultz, M Bagga
1University of Cambridge, Department of Pathology, Cambridge, UK.
Free Radical Research
|August 14, 1998
Summary
In diabetes mellitus, glucose modification of low-density lipoprotein (LDL) accelerates atherosclerosis. Both glucose modification (glycation) and oxidation of LDL increase its ability to attract immune cells, contributing to vascular damage.
Area of Science:
- Biochemistry
- Immunology
- Cardiovascular Research
Background:
- Diabetes mellitus accelerates atherosclerosis, a vascular disease.
- Glucose interaction with lipoproteins like low-density lipoprotein (LDL) may drive this damage.
- Understanding these interactions is crucial for managing diabetic vascular complications.
Purpose of the Study:
- To investigate how glucose-modified LDL affects human monocyte chemotaxis.
- To determine the roles of oxidation and glycation in making LDL chemotactic.
- To explore the combined effects of glycation and oxidation on LDL's vascular impact.
Main Methods:
- Assessing LDL chemotactic activity after modification with glucose.
- Utilizing copper (Cu(II)) to mediate LDL oxidation.
- Employing inhibitors like DETAPAC and aminoguanidine to differentiate oxidation and glycation effects.
- Measuring monocyte migration in response to modified LDL.
Main Results:
- Glucose potentiated Cu(II)-mediated LDL oxidation in a dose-dependent manner, enhancing chemotactic activity.
- Glucose alone, with minimal oxidation, also increased LDL's chemotactic properties.
- Inhibiting LDL oxidation did not fully abolish the chemotactic activity of glycated oxidized LDL.
Conclusions:
- Both LDL oxidation and glycation significantly contribute to increased monocyte chemotaxis.
- These modifications of LDL by glucose play a role in the accelerated atherosclerosis seen in diabetes.
- Targeting both glycation and oxidation pathways may be beneficial in preventing diabetic vascular disease.